MedTrace Logo

Medical Cannabis Observational Study for Antiemetic Intervention in Chemotherapy

NCT07374939 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-06-09

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the associations between patient-directed medical cannabis use and chemotherapy-induced nausea and vomiting (CINV), as well as other treatment-related symptoms, among patients receiving chemotherapy that is known to cause nausea. The main questions it aims to answer are:

* Is patient-directed medical cannabis use associated with reduced nausea severity during chemotherapy treatment?
* Is-patient directed medical cannabis use associated with improved CINV control?
* Is patient directed medical cannabis use associated with improved appetite during chemotherapy treatment?
* Is patient-medical cannabis use associated with reduced treatment-related side effects, such as fatigue, sleep disturbances, general pain, and peripheral neuropathic pain?

Researchers will compare participants who report using medical cannabis with participants who do not report using medical cannabis to determine whether differences exist in nausea, CINV outcomes, and other treatment-related symptoms.

Participants will be followed over the course of 3 chemotherapy cycles, and asked to complete questionnaires, nausea diaries, and partake in a blood sample collection. Study participation can last from 6 - 12 weeks, depending on their prescribed chemotherapy cycle frequency.

Conditions

  • Nausea and Vomiting Chemotherapy-Induced

Interventions

DRUG

Medical Cannabis

Participant-directed medical cannabis use

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2028-03-01
Completion
2028-03-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07374939 on ClinicalTrials.gov